NTM Lecture Series for Providers

October 19-20, 2017
National Jewish Health in Denver, Colorado

Outcomes Summary Report
Grant ID: ConTrack 4253
Background

**Executive Summary:** The NTM Lecture Series is an annual symposium featuring key opinion leaders from across the U.S. leading lectures and panel discussions covering topics such as epidemiology of NTM, genomic approaches to NTM, host susceptibility, radiologic evaluation, treatment of slow and rapidly growing mycobacteria, novel therapies, and surgical management. The Provider Course was held at the Molly Blank Conference Center at National Jewish Health in Denver, Colorado October 19-20, 2017. There were 50 health care providers in attendance.

**Target Audience:** The target audience was family physicians and internal medicine physicians, along with pulmonologists, physician assistants, and other health care professionals who diagnose and treat patients with NTM. The program incorporated live didactic lectures, as well as interactive cases using Audience Response System (ARS) keypads for an immediate test of knowledge and feedback. The program also included two panel discussions with the expert faculty and optional laboratory tours.
Dashboard

Attendees likely to make a change in practice: 100%

Activity met learning objectives: 100%

Activity addressed strategies for overcoming barriers: 95%

50 Learners/Certificates

80% Prescribers

Overall relative knowledge gain from pre- to post-activity: 14%

Estimated # of patients seen per month by participants: 370+
Dashboard

Key Lessons Learned
- Treatment strategies for rapid growing NTM
- Better understanding of therapeutics
- Importance of species identification/susceptibility testing
- Patient perspective and education, environmental considerations
- Absolute need for a multi-disciplinary approach in diagnosis and management of NTM infections

Needs for Further Education
- Extra-pulmonary manifestations of NTM
- Standard and investigational treatment options
- Difficult cases, immunologic work up and treatment
- Structured protocols for evaluation and monitoring of clinical progress and drug toxicity to guide management of NTM
- Non-pharmacologic treatment for NTM

What Attendees are Saying
“Very impressed with the overall program, the information discussed in an efficient way and the availability of the faculty for discussion.”

“Excellent Course – I have recommended your program to several of my colleagues.”

“This course continues in its tradition of excellence. My congratulations to the course directors and faculty and support staff.”

“This is a great course. So happy it exists!”
## Level 1: Participation

### Designation

- **MD/DO**: 78%
- **PA**: 16%
- **PharmD**: 4%
- **Other**: 2%

### Specialty

- **Infectious Disease**: 66.0%
- **Pulmonary**: 12.0%
- **Internal Medicine**: 4.0%
- **Other**: 18.0%

*Total N = 50*
Level 2 and 3 Outcomes: Satisfaction/Learning

Attendees evaluate how well the activity:

- Improved your ability to treat/manage patients: 90.9% Excellent, 9.1% Good
- Enhanced your ability to apply the learning objectives to practice: 90.5% Excellent, 9.5% Good
- Reinforced and/or improved current skills: 90.9% Excellent, 9.1% Good
- Met educational needs: 90.9% Excellent, 9.1% Good

N=22
Level 3 and 4 outcomes were measured by comparing participants’ pre- and post-test answers. The attendees’ responses to these questions demonstrated that participants gained knowledge as a result of the activity.
Level 4 Outcomes: Competence

100% report that they are “somewhat likely” to “extremely likely” to make changes in practice as a result of this activity; those changes include:

- Modify treatment plans: 81.8%
- Use alternative communication methodologies with patients and families: 40.9%
- Incorporate different diagnostic strategies into patient evaluation: 36.4%
- Change my screening/prevention practice: 45.5%

N=22
Evaluation

• **100%** report the activity was “excellent” to “good” at meeting the learning objectives

• **95.5%** report the activity addressed strategies for overcoming barriers to care

• **100%** report the activity was evidence based and clinically relevant

• **95.5%** reported that the material was presented in an objective manner and free of commercial bias

N=22
About NJH

✓ Largest pulmonary division in the world and the only hospital whose principal focus is respiratory and related diseases.

✓ #1 or #2 ranking in Pulmonology category by U.S. News & World Report (since category was added in 1997).

✓ Top 7 percent of institutions funded by the National Institutes of Health, an extraordinary achievement for an institution of NJH’s size.

✓ Designated as a Specialized Center of Research for ILD by The National Institute of Health.

✓ 30 doctors named to “America’s Top Doctors” in 2015.

✓ The NJH COPD clinic is the largest single COPD clinic in the nation and was recently recognized by U.S. News and World Report for its expertise in treating COPD, receiving a “high-performing” designation.